# Mark T Osterman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7163024/publications.pdf

Version: 2024-02-01

| 50 | 2,709 | 279798 | 243625 |
|---|---|---|---|
| papers | citations | 23 h-index | 44 g-index |

| 52 | 52 | 52 | 2692 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 116-125.e5. | 4.4 | 23 |
| 2 | Realâ€world multicentre observational study including population pharmacokinetic modelling to evaluate the exposureâ€“response relationship of vedolizumab in inflammatory bowel disease: <scp>ERELATE</scp> Study. Alimentary Pharmacology and Therapeutics, 2022, 56, 463-476. | 3.7 | 12 |
| 3 | Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, 66, 3563-3569. | 2.3 | 3 |
| 4 | Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE). Inflammatory Bowel Diseases, 2021, 27, 207-214. | 1.9 | 15 |
| 5 | Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2021, 27, 677-685. | 1.9 | 5 |
| 6 | The Impact of Introducing Patient-Reported Inflammatory Bowel Disease Symptoms via Electronic Survey on Clinic Visit Length, Patient and Provider Satisfaction, and the Environment Microbiome. Inflammatory Bowel Diseases, 2021, 27, 746-750. | 1.9 | 1 |
| 7 | A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2014-2025. | 0.4 | 93 |
| 8 | Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. American Journal of Gastroenterology, 2021, 116, 1007-1014. | 0.4 | 31 |
| 9 | Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2020, 26, 1554-1561. | 1.9 | 12 |
| 10 | Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohnâ€™s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflammatory Bowel Diseases, 2020, 26, 103-111. | 1.9 | 34 |
| 11 | Self-help Cognitive Behavioral Therapy Improves Health-Related Quality of Life for Inflammatory Bowel Disease Patients: A Randomized Controlled Effectiveness Trial. Journal of Clinical Psychology in Medical Settings, 2020, 27, 467-479. | 1.4 | 21 |
| 12 | Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age. Clinical Gastroenterology and Hepatology, 2020, 18, 2262-2268. | 4.4 | 31 |
| 13 | Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2020, 9, 3142. | 2.4 | 17 |
| 14 | Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Alimentary Pharmacology and Therapeutics, 2019, 49, 408-418. | 3.7 | 60 |
| 15 | Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. Digestive Diseases and Sciences, 2019, 64, 2478-2488. | 2.3 | 9 |
| 16 | A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 1550-1558. | 1.9 | 10 |
| 17 | Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2019, 25, 925-936. | 1.9 | 11 |
| 18 | Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. Gastroenterology, 2018, 154, 1201-1202. | 1.3 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-Î±-Directed Therapy for Inflammatory Bowel Disease. American Journal of Gastroenterology, 2018, 113, 405-417. | 0.4 | 99 |
| 20 | Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 761-767. | 2.3 | 21 |
| 21 | Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflammatory Bowel Diseases, 2018, 24, 217-226. | 1.9 | 9 |
| 22 | Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2018, 24, 2266-2271. | 1.9 | 65 |
| 23 | Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 804-810. | 1.3 | 91 |
| 24 | Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 598-599. | 4.4 | 0 |
| 25 | Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology, 2018, 155, 1098-1108.e9. | 1.3 | 67 |
| 26 | Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clinical Gastroenterology and Hepatology, 2017, 15, 1580-1588.e3. | 4.4 | 181 |
| 27 | Infliximab vs Adalimumab for UC: IsÂThere A Difference?. Clinical Gastroenterology and Hepatology, 2017, 15, 1197-1199. | 4.4 | 2 |
| 28 | Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1638-1639. | 4.4 | 0 |
| 29 | Clozapine-induced acute gastrointestinal necrosis: a case report. Journal of Medical Case Reports, 2017, 11, 270. | 0.8 | 13 |
| 30 | Crohnâ€™s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. American Journal of Gastroenterology, 2016, 111, 1806-1815. | 0.4 | 57 |
| 31 | Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1813-1818. | 0.9 | 90 |
| 32 | Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatology, 2016, 152, 164. | 4.1 | 131 |
| 33 | Effectiveness and Safety of Immunomodulators With Antiâ€“Tumor Necrosis Factor Therapy in Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1293-1301.e5. | 4.4 | 65 |
| 34 | Can Colonoscopy Reduce the Risk of Colon Cancer and Mortality in Patients With Inflammatory Bowel Disease?. Clinical Gastroenterology and Hepatology, 2015, 13, 1702-1703. | 4.4 | 0 |
| 35 | Natalizumab for Crohnâ€™s Disease: Down but Not Out. Clinical Gastroenterology and Hepatology, 2015, 13, 1926-1928. | 4.4 | 7 |
| 36 | Reply. Clinical Gastroenterology and Hepatology, 2015, 13, 210-211. | 4.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2014, 12, 1887-1893.e3. | 4.4 | 75 |
| 38 | Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 811-817.e3. | 4.4 | 102 |
| 39 | Reply. Gastroenterology, 2014, 147, 540-541. | 1.3 | 0 |
| 40 | Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease. Gastroenterology, 2014, 146, 941-949.e2. | 1.3 | 172 |
| 41 | Medical Management of Crohn Disease. Clinics in Colon and Rectal Surgery, 2013, 26, 067-074. | 1.1 | 15 |
| 42 | Mucosal Healing in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2013, 47, 212-221. | 2.2 | 48 |
| 43 | A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 36-41.e1. | 4.4 | 422 |
| 44 | No Increased Risk of Myocardial Infarction Among Patients With Ulcerative Colitis or Crohn's Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 875-880. | 4.4 | 76 |
| 45 | To TNF or not to TNF: That is the question. Inflammatory Bowel Diseases, 2010, 16, 1993-1995. | 1.9 | 0 |
| 46 | Big risk, small risk: Small bowel cancer in CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 1434-1435. | 1.9 | 1 |
| 47 | Reformulation of an aminosalicylate: An example of the importance of pill burden on medical compliance rates. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 41. | 0.8 | 1 |
| 48 | Current and future anti-TNF therapy for inflammatory bowel disease. Current Treatment Options in Gastroenterology, 2007, 10, 195-207. | 0.8 | 24 |
| 49 | Infliximab in Fistulizing Crohn's Disease. Gastroenterology Clinics of North America, 2006, 35, 795-820. | 2.2 | 24 |
| 50 | Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-Analysis. Gastroenterology, 2006, 130, 1047-1053. | 1.3 | 440 |